Menu Search
Equities

Lupin Ltd

LUPIN:NSI

Lupin Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)2,069.15
  • Today's Change28.15 / 1.38%
  • Shares traded335.40k
  • 1 Year change+69.88%
  • Beta0.7405
Data delayed at least 15 minutes, as of Nov 22 2024 09:39 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy6
Outperform9
Hold9
Sell6
Strong Sell2

Share price forecast in INR

The 32 analysts offering 12 month price targets for Lupin Ltd have a median target of 2,254.50, with a high estimate of 2,750.00 and a low estimate of 964.00. The median estimate represents a 10.46% increase from the last price of 2,041.00.
High34.7%2,750.00
Med10.5%2,254.50
Low-52.8%964.00

Dividends in INR

In 2024, Lupin Ltd reported a dividend of 8.00 INR, which represents a 100.00% increase over last year. The 22 analysts covering the company expect dividends of 8.35 INR for the upcoming fiscal year, an increase of 4.39%.
Div growth (TTM)100.00%
More ▼

Earnings history & estimates in INR

On Nov 07, 2024, Lupin Ltd reported 2nd quarter 2025 earnings of 18.64 per share. This result exceeded the 16.25 consensus of the 5 analysts covering the company and exceeded last year's 2nd quarter results by 73.88%.
The next earnings announcement is expected on Feb 05, 2025.
Average growth rate+28.25%
Lupin Ltd reported annual 2024 earnings of 41.87 per share on May 06, 2024.
Average growth rate+247.80%
More ▼

Revenue history & estimates in INR

Lupin Limited had 2nd quarter 2025 revenues of 56.73bn. This bettered the 55.34bn consensus of the 17 analysts covering the company. This was 19.62% above the prior year's 2nd quarter results.
Average growth rate+3.20%
Lupin Limited had revenues for the full year 2024 of 200.11bn. This was 22.99% above the prior year's results.
Average growth rate+7.22%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.